{"id": "RsLTmdwAAAAJ", "citedby": 772, "citedby5y": 584, "hindex": 12, "hindex5y": 12, "i10index": 13, "i10index5y": 12, "coauthors": [], "name": "Randy F. Sweis", "affiliation": "University of Chicago", "interests": ["Cancer Immunology", "Genitourinary Oncology", "Developmental Therapeutics", "Phase I Trials", "Clinical Pharmacology"], "cites_per_year": {"2003": 2, "2004": 2, "2005": 5, "2006": 20, "2007": 8, "2008": 15, "2009": 20, "2010": 18, "2011": 14, "2012": 16, "2013": 30, "2014": 25, "2015": 21, "2016": 39, "2017": 95, "2018": 108, "2019": 161, "2020": 157}, "publications": [{"bib": {"title": "Molecular drivers of the non\u2013T-cell-inflamed tumor microenvironment in urothelial bladder cancer", "year": "2016"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:_FxGoFyzp5QC", "citedby": "131"}, {"bib": {"title": "Silver-catalyzed [2+ 2] cycloadditions of siloxy alkynes", "year": "2004"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:u5HHmVD_uO8C", "citedby": "128"}, {"bib": {"title": "Br\u00f8nsted acid-promoted cyclizations of 1-siloxy-1, 5-diynes", "year": "2005"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:Y0pCki6q_DkC", "citedby": "85"}, {"bib": {"title": "WNT/\u03b2-catenin pathway activation correlates with immune exclusion across human cancers", "year": "2019"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:mVmsd5A6BfQC", "citedby": "78"}, {"bib": {"title": "T cell\u2013inflamed versus non-T cell\u2013inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection", "year": "2018"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:qxL8FJ1GzNcC", "citedby": "63"}, {"bib": {"title": "Tumor endothelial inflammation predicts clinical outcome in diverse human cancers", "year": "2012"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:u-x6o8ySG0sC", "citedby": "43"}, {"bib": {"title": "Do clinicians know which of their patients have central venous catheters?: a multicenter observational study", "year": "2014"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:9yKSN-GCB0IC", "citedby": "40"}, {"bib": {"title": "Correlation of WNT/\u03b2-catenin pathway activation with immune exclusion across most human cancers.", "year": "2016"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:ufrVoPGSRksC", "citedby": "28"}, {"bib": {"title": "Mechanistic and pharmacologic insights on immune checkpoint inhibitors", "year": "2017"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:MXK_kJrjxJIC", "citedby": "27"}, {"bib": {"title": "Analysis of impact of post-treatment biopsies in phase I clinical trials", "year": "2016"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:Tyk-4Ss8FVUC", "citedby": "27"}, {"bib": {"title": "Emerging role of immunotherapy in urothelial carcinoma\u2014Immunobiology/biomarkers", "year": "2016"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:UebtZRa9Y70C", "citedby": "19"}, {"bib": {"title": "Concurrent EGFR mutation and ALK translocation in non-small cell lung cancer", "year": "2016"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:eQOLeE2rZwMC", "citedby": "18"}, {"bib": {"title": "Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer. Cancer Immunol Res. 2016; 4: 563\u2013568. doi: 10.1158/2326-6066"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:YOwf2qJgpHMC", "citedby": "10"}, {"bib": {"title": "Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer", "year": "2018"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:_kc_bZDykSQC", "citedby": "8"}, {"bib": {"title": "Molecular drivers of the non-T cell-inflamed tumor microenvironment in urothelial bladder cancer.", "year": "2015"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:5nxA0vEk-isC", "citedby": "8"}, {"bib": {"title": "Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop", "year": "2019"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:-f6ydRqryjwC", "citedby": "7"}, {"bib": {"title": "Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy", "year": "2019"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:7PzlFSSx8tAC", "citedby": "7"}, {"bib": {"title": "Intratumoral adaptive immunosuppression and type 17 immunity in mismatch repair proficient colorectal tumors", "year": "2019"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:qUcmZB5y_30C", "citedby": "6"}, {"bib": {"title": "Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic biomarker for pazopanib in metastatic renal carcinoma", "year": "2017"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:roLk4NBRz8UC", "citedby": "6"}, {"bib": {"title": "Actinomyces-Induced Inflammatory Pseudotumor of the Lymph Node Mimicking Scrofula", "year": "2011"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:d1gkVwhDpl0C", "citedby": "6"}, {"bib": {"title": "Clinical activity of olaparib in urothelial bladder cancer with DNA damage response gene mutations", "year": "2018"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:Wp0gIr-vW9MC", "citedby": "5"}, {"bib": {"title": "31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two", "year": "2016"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:0EnyYjriUFMC", "citedby": "4"}, {"bib": {"title": "Preliminary results of PROCLAIM-CX-2009, a first-in-human, dose-finding study of the probody\u2122 drug conjugate CX-2009 in patients with advanced solid tumors", "year": "2019"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:e5wmG9Sq2KIC", "citedby": "3"}, {"bib": {"title": "Hyperprogression\u2014Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer", "year": "2019"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:ZeXyd9-uunAC", "citedby": "3"}, {"bib": {"title": "Eligibility and radiologic assessment in adjuvant clinical trials in bladder cancer", "year": "2019"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:isC4tDSrTZIC", "citedby": "2"}, {"bib": {"title": "Cutting the brakes: immunotherapy with PD-1 inhibitors", "year": "2017"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:Zph67rFs4hoC", "citedby": "2"}, {"bib": {"title": "Molecular characterization of immune exclusion in small-cell lung cancer.", "year": "2016"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:kNdYIx-mwKoC", "citedby": "2"}, {"bib": {"title": "Sitravatinib in combination with nivolumab demonstrates clinical activity in platinum-experienced patients with urothelial carcinoma (UC) who progressed on prior immune \u2026", "year": "2019"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:maZDTaKrznsC", "citedby": "1"}, {"bib": {"title": "Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma", "year": "2019"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:aqlVkmm33-oC", "citedby": "1"}, {"bib": {"title": "Obviating the Need for Serial Biopsies Through Random Assignment", "year": "2017"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:Se3iqnhoufwC", "citedby": "1"}, {"bib": {"title": "Reply to TA Yap et al", "year": "2016"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:WF5omc3nYNoC", "citedby": "1"}, {"bib": {"title": "Analysis of impact of post-treatment biopsies in phase I clinical trials.", "year": "2014"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:KlAtU1dfN6UC", "citedby": "1"}, {"bib": {"title": "Substituted Aminopyrimidines as Cholecystokinin-1 Receptor Modulators", "year": "2010"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:qjMakFHDy7sC", "citedby": "1"}, {"bib": {"title": "P854 Construction of the immune landscape of durable response to checkpoint blockade therapy by integrating publicly available datasets", "year": "2020"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:NMxIlDl6LWMC", "citedby": "0"}, {"bib": {"title": "Novel Immunotherapies and Novel Combinations of Immunotherapy for Metastatic Melanoma", "year": "2020"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:hMod-77fHWUC", "citedby": "0"}, {"bib": {"title": "Germline genetic contribution to the immune landscape of cancer", "year": "2020"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:blknAaTinKkC", "citedby": "0"}, {"bib": {"title": "Methods to assess anticancer immune responses in orthotopic bladder carcinomas", "year": "2020"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:TFP_iSt0sucC", "citedby": "0"}, {"bib": {"title": "Germline genetic variation affects the immune response in cancer", "year": "2019"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:JV2RwH3_ST0C", "citedby": "0"}, {"bib": {"title": "Integrating CD8 and CD4 effector neo-epitope content with regulatory T cell epitope exclusion is a superior prognostic biomarker for bladder cancer patient compared to their \u2026", "year": "2019"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:M3NEmzRMIkIC", "citedby": "0"}, {"bib": {"title": "Variation in the commensal urinary microbiome is associated with response to Bacillus Calmette-Guerin (BCG) immunotherapy in early stage urothelial bladder cancer", "year": "2019"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:k_IJM867U9cC", "citedby": "0"}, {"bib": {"title": "The commensal urinary microbiome as a predictor of response to Bacillus Calmette-Guerin (BCG) immunotherapy in non-muscle invasive bladder cancer", "year": "2019"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:R3hNpaxXUhUC", "citedby": "0"}, {"bib": {"title": "Triple-negative breast cancer cell-intrinsic glucocorticoid receptor activity and modulation of the immune microenvironment", "year": "2019"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:TQgYirikUcIC", "citedby": "0"}, {"bib": {"title": "Multichannel immunofluorescence imaging to assess the immune composition of tumor microenvironment in bladder cancer", "year": "2019"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:HDshCWvjkbEC", "citedby": "0"}, {"bib": {"title": "A randomized phase II study of atezolizumab plus recombinant human IL-7 (CYT107) or atezolizumab alone in patients with locally advanced or metastatic urothelial carcinoma (mUC \u2026", "year": "2019"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:hFOr9nPyWt4C", "citedby": "0"}, {"bib": {"title": "MP43-11 CHARACTERIZATION OF THE URINARY MICROBIOME IN PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER TREATED WITH BACILLUS CALMETTE-GU\u00e9RIN IMMUNOTHERAPY", "year": "2019"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:IWHjjKOFINEC", "citedby": "0"}, {"bib": {"title": "Association of the commensal urinary microbiome with response to Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy in nonmuscle invasive bladder cancer.", "year": "2019"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:QIV2ME_5wuYC", "citedby": "0"}, {"bib": {"title": "Abstract B089: Application of precision cancer immunotherapy design tools to bladder cancer: Non-self-like neoepitopes as a prognostic biomarker", "year": "2019"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:9ZlFYXVOiuMC", "citedby": "0"}, {"bib": {"title": "Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assays", "year": "2019"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:YFjsv_pBGBYC", "citedby": "0"}, {"bib": {"title": "Phase Ib/II study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally \u2026", "year": "2018"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:dhFuZR0502QC", "citedby": "0"}, {"bib": {"title": "925TiP Phase Ib/II study to evaluate the safety, tolerability and pharmacokinetics of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients with locally \u2026", "year": "2018"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:4DMP91E08xMC", "citedby": "0"}, {"bib": {"title": "Low clinical adoption of tumor genomic profiling: cause for concern?", "year": "2018"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:4TOpqqG69KYC", "citedby": "0"}, {"bib": {"title": "Variants and Concomitant Tumor Morphologies Associated with Gene Expression Subtypes of Bladder Cancer (BC) in Radical Cystectomy (RC) Specimens", "year": "2018"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:M3ejUd6NZC8C", "citedby": "0"}, {"bib": {"title": "Pseudoprogression manifesting as recurrent ascities with anti-PD-1 therapy", "year": "2017"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:L8Ckcad2t8MC", "citedby": "0"}, {"bib": {"title": "Genomic analysis of bladder cancer immunophenotypes", "year": "2017"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:ULOm3_A8WrAC", "citedby": "0"}, {"bib": {"title": "CHARACTERIZATION OF NON-T CELL-INFLAMED BLADDER CANCER TO ENHANCE IMMUNOTHERAPY RESPONSE", "year": "2017"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:8k81kl-MbHgC", "citedby": "0"}, {"bib": {"title": "Validation of activated molecular pathways in non-T cell-inflamed urothelial bladder cancer (UBC).", "year": "2016"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:3fE2CSJIrl8C", "citedby": "0"}, {"bib": {"title": "BIOMARKER OUTCOMES IN EARLY PHASE ONCOLOGY TRIALS INCLUDING NON-DIAGNOSTIC BIOPSIES.: PII-031", "year": "2016"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:W7OEmFMy1HYC", "citedby": "0"}, {"bib": {"title": "Characterization of oncogenic pathways linked with T cell exclusion in urothelial bladder cancer", "year": "2015"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:zYLM7Y9cAGgC", "citedby": "0"}, {"bib": {"title": "Dynamic contrast enhanced-MRI (DCE-MRI) as a pharmacodynamic biomarker for pazopanib (PZ) in metastatic renal carcinoma (RC).", "year": "2015"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:hqOjcs7Dif8C", "citedby": "0"}, {"bib": {"title": "Expression of MET and HGF in bladder cancer tumorigenesis and invasion", "year": "2012"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:2osOgNQ5qMEC", "citedby": "0"}, {"bib": {"title": "Application of precision cancer immunotherapy design tools to bladder cancer: Non-self-like neo-epitopes as a prognostic biomarker"}, "source": "citations", "id_citations": "RsLTmdwAAAAJ:hC7cP41nSMkC", "citedby": "0"}]}